enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the company’s stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $15.00, for a total transaction of $717,810.00. Following the completion of the sale, the insider now directly owns 3,036,153 shares in the company, valued at $45,542,295. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
De Solidarite Des Travai Fonds also recently made the following trade(s):
- On Thursday, April 18th, De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock. The shares were sold at an average price of $15.01, for a total transaction of $68,670.75.
enGene Trading Down 0.3 %
Shares of ENGN opened at $14.80 on Tuesday. The stock has a fifty day moving average price of $16.11. enGene Holdings Inc. has a 12-month low of $6.69 and a 12-month high of $43.00.
Analyst Ratings Changes
Check Out Our Latest Analysis on ENGN
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Vivo Capital LLC bought a new stake in shares of enGene during the fourth quarter worth about $6,264,000. Omega Fund Management LLC bought a new stake in enGene during the 4th quarter worth approximately $10,441,000. BVF Inc. IL purchased a new stake in shares of enGene in the fourth quarter worth approximately $20,777,000. Finally, Fcpm Iii Services B.V. bought a new position in shares of enGene in the fourth quarter valued at approximately $80,097,000. 64.16% of the stock is owned by institutional investors.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Recommended Stories
- Five stocks we like better than enGene
- Best Aerospace Stocks Investing
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Merger or Not, Albertson’s Companies is a Good Buy
- What Are Trending Stocks? Trending Stocks Explained
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.